Autopsy report · NCT03248141
Understanding Hemophilia A and B Drug Dosage Administration Patterns
Cause of deathSlow enrollment
“Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. See details in Description section.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 6 months before it stopped.
- 11 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Hemophilia A; Hemophilia B
- Interventions
- Hemophilia B standard half-life; Hemophilia B extended half-life; Hemophilia A standard half-life; Hemophilia A extended half-life
- Participants
- 11
- Sites
- 3
- Countries
- United States
Trials that died the same way
- Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.
“Study stopped due to difficulties in patient recruitment” - Focus on Fibre Study
“There were issues with recruitment so study was stopped” - Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
“The study was stopped due to recruitment difficulties” - Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)
“Study was stopped due to insufficient recruitment.” - High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery
“Study halted prematurely, prior to enrollment of first patient, due to recruiting problems.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.